ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.81 USD
+0.07 (1.04%)
Updated May 3, 2024 04:00 PM ET
After-Market: $6.80 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADMA 6.81 +0.07(1.04%)
Will ADMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Other News for ADMA
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
3 'Buy-Rated' Biotech Stocks Under $10
Biotech Alert: Searches spiking for these stocks today
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Kaitlin Kestenberg Promoted to COO at ADMA Biologics